FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION							
	Washington, D.C. 20549							
Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	E						
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	ŀ						

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response: 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person [*]				2. Issuer Name and Ticker or Trading Symbol <u>Oncology Institute, Inc.</u> [TOI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Castle Jerem	<u>1y</u>	Onco	<u>ology Institute</u>	<u>, Inc.</u>	[TC	ן ונ		Director	10% C	Owner				
(Last) C/O THE ONC	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/21/2024					X	Officer (give title Other (specify below) below) Chief Operating Officer				
18000 STUDEBAKER RD, SUITE 800				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)								X	, , ,					
CERRITOS	СА	90703								Form filed by Mor Person	e than One Repo	orting		
(City)	(State)	(Zip)	Rule	Rule 10b5-1(c) Transaction Indication										
				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
		Table I - Nor	n-Derivative S	Securities Acq	uired,	Disp	oosed of, o	r Bene	ficially	Owned				
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Disposed Of (5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V		Amount (A) or (D) P		Price	Transaction(s) (Instr. 3 and 4)		(
Common Stock			05/21/2024		Α		70,120 ⁽¹⁾	A	\$0.0	82,460	D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Non- Qualified Stock Option (right to buy)	\$2	05/21/2024		А		175,299		(2)	05/21/2034	Common Stock	175,299	\$0.0	175,299	D	

Explanation of Responses:

1. Represents RSUs with 1/4th of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates

2. The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, subject to continue service with the Company through such vesting dates.



05/23/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 4

Attorney-in-Fact For: Jeremy Castle

Date